These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21505425)

  • 1. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.
    Hadac EM; Kelly EJ; Russell SJ
    Mol Ther; 2011 Jun; 19(6):1041-7. PubMed ID: 21505425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
    Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
    J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA.
    Elsedawy NB; Nace RA; Russell SJ; Schulze AJ
    Mol Ther Oncolytics; 2020 Jun; 17():484-495. PubMed ID: 32529026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
    Skelding KA; Barry RD; Shafren DR
    Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
    Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
    J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
    Relph K; Annels N; Smith C; Kostalas M; Pandha H
    Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
    Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR
    Virol J; 2011 Jan; 8():22. PubMed ID: 21241513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent oncolytic activity of human enteroviruses against human prostate cancer.
    Berry LJ; Au GG; Barry RD; Shafren DR
    Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic
    Karbalaee R; Mehdizadeh S; Ghaleh HEG; Izadi M; Kondori BJ; Dorostkar R; Hosseini SM
    Curr Cancer Drug Targets; 2024; 24(9):967-974. PubMed ID: 38310465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.
    Skelding KA; Barry RD; Shafren DR
    Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
    Au GG; Lincz LF; Enno A; Shafren DR
    Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative one-shot systemic virotherapy in murine myeloma.
    Naik S; Nace R; Federspiel MJ; Barber GN; Peng KW; Russell SJ
    Leukemia; 2012 Aug; 26(8):1870-8. PubMed ID: 22425894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.
    Burnett WJ; Burnett DM; Parkman G; Ramstead A; Contreras N; Gravley W; Holmen SL; Williams MA; VanBrocklin MW
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.
    Au GG; Lindberg AM; Barry RD; Shafren DR
    Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncolytic coxsackievirus therapy as an immunostimulator].
    Miyamoto S; Sagara M; Kohara H; Tani K
    Rinsho Ketsueki; 2017; 58(8):977-982. PubMed ID: 28883283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.
    Bailey K; Kirk A; Naik S; Nace R; Steele MB; Suksanpaisan L; Li X; Federspiel MJ; Peng KW; Kirk D; Russell SJ
    PLoS One; 2013; 8(9):e73759. PubMed ID: 24040057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of coxsackievirus A21 in oncology.
    Bradley S; Jakes AD; Harrington K; Pandha H; Melcher A; Errington-Mais F
    Oncolytic Virother; 2014; 3():47-55. PubMed ID: 27512662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
    Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
    Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodology.
    Israelsson S; Sävneby A; Ekström JO; Jonsson N; Edman K; Lindberg AM
    Invest New Drugs; 2014 Dec; 32(6):1063-70. PubMed ID: 25052234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.